繁體
简体中文
繁體中文

Avantis國際大型價值股主動型ETF AVIV 深 滬

已收盤 11-20 16:00:00 美东时间

74.07

-1.810

-2.39%

华盛通華盛通
立即下載
  • 最 高75.59
  • 今 開75.29
  • 成交量 66.92万股
  • 最 低 74.02
  • 昨 收 75.88
  • 總市值 195.10万
  • 52周最高 83.6674
  • 市盈率 靜 --
  • 換手率 2540.74%
  • 52周最低 67.2644
  • 委 比 0.00%
  • 總股本 2.63万
  • 歷史最高 83.6674
  • 量 比 3.30
  • 振 幅 2.07%
  • 歷史最低 30.0207
  • 每 手 1
  • 風險率 4.27%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Quantum X Labs Demonstrates Accurate Quantum Radiation Simulation on IBM Quantum Computer

    Quantum X Labs achieved a milestone by successfully executing a 16-qubit quantum algorithm on IBM's Fez processor, simulating photon transport through shielding materials. The experiment demonstrated high accuracy, closely matching classical simulations, and highlighted the potential for quantum algorithms to reduce computational resources in nuclear modeling. The algorithm accurately reproduced photon detection probabilities, validated on real q...

    11-20 12:56

  •  Gix Deploys New Advanced AI-Powered L4 Autonomous Robot with Multi-Environment Navigation and Smart Access Capabilities at One of the World’s Top Hospitals

    Gix Internet Ltd. announced the deployment of an Ottonomy autonomous delivery robot at Sheba Medical Center, Israel's largest hospital. The robot joins Sheba's existing fleet, managed through deliverz.ai's unified AI-powered platform, enabling coordination of robots from different manufacturers alongside human transport teams. This robot-agnostic approach allows hospitals to select optimal solutions for each task while simplifying operations and ...

    11-17 13:39

  • Nasus Pharma Appoints Nir Sassi as Chief Financial Officer

    Nasus Pharma appoints Nir Sassi as CFO, bringing 25 years of experience in biopharmaceutical finance and capital markets. Sassi previously served as CFO of two Nasdaq-listed companies and will support Nasus as it advances its NS002 pivotal Phase 3 study and pre-commercial plans. The company expects to initiate the study in Q4 2026 and release topline data in Q1 2027. Sassi's expertise is expected to strengthen Nasus' financial and operational cap...

    11-16 13:00

  • HUB Announces Reverse Share Split

    HUB Security Ltd. announced a 1-for-20 reverse share split of its ordinary shares, effective November 12, 2026. The split will reduce the number of outstanding shares from 19,299,894 to 964,994, with fractional shares rounded down. The shares will resume trading on November 13 under the same symbol "HUBC" but with a new CUSIP number. The reverse split aims to increase the per-share trading price and maintain compliance with Nasdaq's minimum bid p...

    11-10 13:30

  • Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026

    Nasus Pharma Ltd. announced that abstracts supporting its investigational intranasal epinephrine powder, NS002, for treating anaphylaxis, have been accepted for presentation at the 2026 ACAAI Annual Scientific Meeting in Phoenix, AZ. The abstract "Enhanced Absorption of Intranasal Powder Epinephrine (FMXIN002) after Single Dose in Adults with Allergic Rhinitis" will be presented orally by Dr. Michael Blaiss on November 14. Three additional poster...

    11-10 13:00

  • Quantum X Labs Expands AI-Powered Quantum Error Correction Program to Three IBM Quantum Processors, Demonstrating Up to 20% Fewer Logical Decoding Failures

    Quantum X Labs Inc. announced a significant advancement in its AI-powered quantum error correction technology, achieving up to 20% fewer logical decoding failures using IBM quantum processors. The milestone builds on earlier research with Google quantum hardware and aims to develop hardware-agnostic solutions for more reliable quantum computing systems. The Company's noise-model calibration methodology enhances decoder performance, supporting its...

    11-09 14:02

  • Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective

    Chemomab Therapeutics and Scipher Medicine announce a proposed merger, with a special shareholder meeting scheduled for December 4, 2026, to vote on the deal. The merger, expected to close in early 2027, aims to create a leading immunology precision medicine company combining Scipher's AI platform and Chemomab's nebokitug drug. The combined company will operate as Scipher Medicine Corporation, with shares trading under the ticker "SCIP" on Nasdaq...

    11-02 13:00

  • Quantum X Labs Announces Cyber Quantum Encryption Breakthrough in Demonstration with IBM Quantum Processor, Heron r2

    Quantum X Labs successfully demonstrated its Qatacomb quantum encryption scheme on IBM's 156-qubit quantum processor, achieving over 90% accuracy in decrypting an image while preventing adversaries without the key from accessing information. The scheme offers information-theoretic security, independent of adversaries' computing power, marking a significant advancement in quantum encryption.

    11-02 12:32

  • Gix Internet: deliverz.ai Granted Patent in South Korea, Expanding International Navigation IP Protection

    Gix Internet Ltd.'s subsidiary, deliverz.ai, has been granted a patent in South Korea for its navigation technology, which uses visual cues from the environment to enhance autonomous vehicle and robot navigation. This patent strengthens Gix's Physical AI strategy, which integrates robots, people, and autonomous systems. The technology is already in use in hospital logistics and aims to expand into other complex environments. The patent adds to ex...

    10-30 11:32

  • Radware to Participate in Upcoming Investor Conferences

    Radware announced it will participate in three investor conferences: the 7th Annual Needham Virtual Tech Week on November 18, 2026; the 30th Annual UBS Global Technology and AI Conference on December 1, 2026, in Scottsdale, AZ; and the 29th Annual Needham Growth Conference on January 12, 2027, in New York, NY. Radware is a global leader in application security and delivery solutions for multi-cloud environments, using AI-driven algorithms to prot...

    10-29 11:00